A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats

Neuropeptides

Volumn 45, Issue 1, 2011, Pages 9-16

  Boules, Mona ^a   Oliveros, Alfredo ^a   Liang, Yanqi ^a   Williams, Katrina ^a   Shaw, Amanda ^a   Robinson, Jessica ^a   Fredrickson, Paul ^a   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

Dopamine receptors; Neurotensin; Nicotine self administration; Norepinephrine; Rat; Reinforcing effect; Serotonin

Indexed keywords

CORTICOSTERONE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MESSENGER RNA; NEUROTENSIN DERIVATIVE; NICOTINE; NORADRENALIN; NT 69 L; SEROTONIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONDITIONING; CONTROLLED STUDY; CORPUS STRIATUM; CORTICOSTERONE BLOOD LEVEL; DOPAMINERGIC TRANSMISSION; MALE; NONHUMAN; NORADRENALIN BRAIN LEVEL; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REINFORCEMENT; SEROTONIN BRAIN LEVEL; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CONDITIONING, OPERANT; CORTICOSTERONE; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROTENSIN; NICOTINE; NOREPINEPHRINE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; SEROTONIN; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 78650772838     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2010.09.003     Document Type: Article

References (50)

1. Alex K.D., Yavanian G.J., McFarlane H.G., Pluto C.P., Pehek E.A. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 2005, 55:242-251.
2. Balfour D.J., Benwell M.E., Birrell C.E., Kelly R.J., Al-Aloul M. Sensitization of the mesoaccumbens dopamine response to nicotine. Pharmacol. Biochem. Behav. 1998, 59:1021-1030.
3. Balfour D.J., Wright A.E., Benwell M.E., Birrell C.E. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav. Brain Res. 2000, 113:73-83.
4. Binder E.B., Kinkead B., Owens M.J., Nemeroff C.B. Neurotensin and dopamine interactions. Pharmacol. Rev. 2001, 53:453-486.
5. Binder E.B., Kinkead B., Owens M.J., Nemeroff C.B. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol. Psychiat. 2001, 50:856-872.
6. Boules M., Cusack B., Zhao L., Fauq A., McCormick D.J., Richelson E. A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. Brain Res. 2000, 865:35-44.
7. Boules M., Iversen I., Oliveros A., Shaw A., Williams K., Fredrickson P., Richelson E. The neurotensin agonist, NT69L, suppresses sucrose-reinforced operant behavior in the rat. Brain Res. 2007, 1127:90-98.
8. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity. Eur. J. Pharmacol. 2001, 426:73-76.
9. Burgevin M.C., Laduron P.M., Quarteronnet D., Chevet T., Castel M.N. Striatal injection of neurotensin increases tyrosine hydroxylase mRNA in substantia nigra. Ann. NY Acad. Sci. 1992, 668:311-313.
10. Clarke P.B., Fu D.S., Jakubovic A., Fibiger H.C. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J. Pharmacol. Exp. Ther. 1988, 246:701-708.
11. Clarke P.B., Kumar R. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br. J. Pharmacol. 1983, 78:329-337.
12. Corrigall W.A., Coen K.M. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 1989, 99:473-478.
13. Corrigall W.A., Franklin K.B., Coen K.M., Clarke P.B. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992, 107:285-289.
14. De Vries T.J., Schoffelmeer A.N., Binnekade R., Raaso H., Vanderschuren L.J. Relapse to cocaine- and heroin-seeking behavior mediated by dopamine D2 receptors is time-dependent and associated with behavioral sensitization. Neuropsychopharmacology 2002, 26:18-26.
15. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 2000, 393:295-314.
16. Domino E.F. Nicotine induced behavioral locomotor sensitization. Prog. Neuropsychopharmacol. Biol. Psychiat. 2001, 25:59-71.
17. Ervin G.N., Birkemo L.S., Nemeroff C.B., Prange A.J. Neurotensin blocks certain amphetamine-induced behaviours. Nature 1981, 291:73-76.
18. Fauq A.H., Hong F., Cusack B., Tyler B.M., Pang Y.P., Richelson E. Synthesis of (2S)-2-amino-3-(1H-4-indolyl) propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides. Tetrahedron: Asymmetry 1998, 9:4127-4134.
19. Feenstra M.G., Vogel M., Botterblom M.H., Joosten R.N., de Bruin J.P. Dopamine and noradrenaline efflux in the rat prefrontal cortex after classical aversive conditioning to an auditory cue. Eur. J. Neurosci. 2001, 13:1051-1054.
20. Fredrickson P., Boules M., Yerbury S., Richelson E. Blockade of nicotine-induced locomotor sensitization by a novel neurotensin analog in rats. Eur. J. Pharmacol. 2003, 458:111-118.
21. Fredrickson P., Boules M., Yerbury S., Richelson E. Novel neurotensin analog blocks the initiation and expression of nicotine-induced locomotor sensitization. Brain Res. 2003, 979:245-248.
22. Fuxe K., Von Euler G., Agnati L.F., Merlo Pich E., O'Connor W.T., Tanganelli S., Li X.M., Tinner B., Cintra A., Carani C., et al. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Ann. NY Acad. Sci. 1992, 668:186-204.
23. George T.P., Verrico C.D., Picciotto M.R., Roth R.H. Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization. J. Pharmacol. Exp. Ther. 2000, 295:58-66.
24. Green T.A., Phillips S.B., Crooks P.A., Dwoskin L.P., Bardo M.T. Nornicotine pretreatment decreases intravenous nicotine self-administration in rats. Psychopharmacology (Berl) 2000, 152:289-294.
25. Heinrichs S.C., Koob G.F. Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J. Pharmacol. Exp. Ther. 2004, 311:427-440.
26. Kalivas P.W., Pierce R.C., Cornish J., Sorg B.A. A role for sensitization in craving and relapse in cocaine addiction. J. Psychopharmacol. 1998, 12:49-53.
27. Kinkead B., Nemeroff C.B. Neurotensin, schizophrenia, and antipsychotic drug action. Int. Rev. Neurobiol. 2004, 59:327-349.
28. Li X.M., Ferraro L., Tanganelli S., O'Connor W.T., Hasselrot U., Ungerstedt U., Fuxe K. Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study. J. Neural. Transm. Gen. Sect. 1995, 102:125-137.
29. Liang Y., Boules M., Shaw A.M., Williams K., Fredrickson P., Richelson E. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Brain Res. 2008, 1231:6-15.
30. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
31. Mandell A.J., Owens M.J., Selz K.A., Morgan W.N., Shlesinger M.F., Nemeroff C.B. Mode matches in hydrophobic free energy eigenfunctions predict peptide-protein interactions. Biopolymers 1998, 46:89-101.
32. Marinelli M., Piazza P.V. Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur. J. Neurosci. 2002, 16:387-394.
33. McBride W.J., Murphy J.M., Ikemoto S. Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behav. Brain Res. 1999, 101:129-152.
34. Mennini T., Taddei C., Codegoni A., Gobbi M., Garattini S. Acute noise stress reduces [3H]5-hydroxytryptamine uptake in rat brain synaptosomes: protective effects of buspirone and tianeptine. Eur. J. Pharmacol. 1993, 241:255-260.
35. Mineur Y.S., Picciotto M.R. Genetics of nicotinic acetylcholine receptors: relevance to nicotine addiction. Biochem. Pharmacol. 2008, 75:323-333.
36. Morilak D.A., Barrera G., Echevarria D.J., Garcia A.S., Hernandez A., Ma S., Petre C.O. Role of brain norepinephrine in the behavioral response to stress. Prog. Neuropsychopharmacol. Biol. Psychiat. 2005, 29:1214-1224.
37. Murphy E.K., Sved A.F., Finlay J.M. Corticotropin-releasing hormone receptor blockade fails to alter stress-evoked catecholamine release in prefrontal cortex of control or chronically stressed rats. Neuroscience 2003, 116:1081-1087.
38. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 2005, 8:1445-1449.
39. Piazza P.V., Le Moal M.L. Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Annu. Rev. Pharmacol. Toxicol. 1996, 36:359-378.
40. Piazza P.V., Maccari S., Deminiere J.M., Le Moal M., Mormede P., Simon H. Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc. Natl. Acad. Sci. USA 1991, 88:2088-2092.
41. Pontieri F.E., Tanda G., Orzi F., Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382:255-257.
42. Ranaldi R., Wise R.A. Blockade of D1 dopamine receptors in the ventral tegmental area decreases cocaine reward: possible role for dendritically released dopamine. J. Neurosci. 2001, 21:5841-5846.
43. Reuter M., Netter P., Rogausch A., Sander P., Kaltschmidt M., Dorr A., Hennig J. The role of cortisol suppression on craving for and satisfaction from nicotine in high and low impulsive subjects. Hum. Psychopharmacol. 2002, 17:213-224.
44. Roberts D.C., Corcoran M.E., Fibiger H.C. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol. Biochem. Behav. 1977, 6:615-620.
45. Roberts D.C., Koob G.F., Klonoff P., Fibiger H.C. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol. Biochem. Behav. 1980, 12:781-787.
46. Robledo P., Maldonado R., Koob G.F. Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat. Brain Res. 1993, 622:105-112.
47. Sabban E.L., Hebert M.A., Liu X., Nankova B., Serova L. Differential effects of stress on gene transcription factors in catecholaminergic systems. Ann. NY Acad. Sci. 2004, 1032:130-140.
48. Shi W.X., Bunney B.S. Roles of intracellular cAMP and protein kinase A in the actions of dopamine and neurotensin on midbrain dopamine neurons. J. Neurosci. 1992, 12:2433-2438.
49. Stein E.A., Pankiewicz J., Harsch H.H., Cho J.K., Fuller S.A., Hoffmann R.G., Hawkins M., Rao S.M., Bandettini P.A., Bloom A.S. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am. J. Psychiat. 1998, 155:1009-1015.
50. Studler J.M., Kitabgi P., Tramu G., Herve D., Glowinski J., Tassin J.P. Extensive co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides 1988, 11:95-100.